Clinical Trials

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04068896 2025-05-29

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Phase 1/2 Completed

89 enrolled 21 charts

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00583349 2025-02-17

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

Phase 1/2 Completed

46 enrolled 11 charts

Urinary Bladder Neoplasms

NCT03240016 2025-01-16

ABLE

36 enrolled 14 charts

Carcinoma, Transitional Cell

NCT03507491 2024-10-04

Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

CNSGastrointestinalGenitourinarySarcoma

24 enrolled

Neoplasms, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

43 enrolled

Cervical Adenocarcinoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Phase 2 Terminated

3 enrolled 9 charts

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03961698 2023-08-14

MARIO-3

Phase 2 Unknown

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 1 Terminated

61 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04475016 2022-06-09

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

29 enrolled

Penile Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

GastrointestinalGenitourinaryGynecologicThoracic

169 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT04148885 2019-11-04

A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer

Phase 1/2 Unknown

44 enrolled

Castration-resistant Prostate Cancer

NCT02911350 2017-10-02

Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

23 enrolled

Prostatic Neoplasms

NCT00683059 2016-10-17

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

48 enrolled

Carcinoma, Transitional Cell

NCT02718742 2016-04-18

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Phase 2 Withdrawn

Recurrent Bladder Urothelial Carcinoma

NCT00521781 2016-03-17

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

Phase 2 Terminated

14 enrolled

Prostatic Neoplasms

NCT00585689 2015-11-30

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

29 enrolled 11 charts

Urinary Bladder Neoplasms

NCT00995488 2015-09-11

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

Phase 2 Terminated

16 enrolled 11 charts

Urinary Bladder Neoplasms

NCT00313599 2014-07-02

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

28 enrolled

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Dysgerminoma, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Central Nervous System Neoplasms

NCT00284752 2012-10-01

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

56 enrolled